This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plutzky, J. Articles by Ridker, P. M. Search for Related Content PubMed PubMed Citation Articles by Plutzky, J. Articles by Ridker, P. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Statins Stroke Related Collections Lipids Risk Factors Brain Circulation and Metabolism Chronic ischemic heart disease

(Circulation. 2001;103:348.)
© 2001 American Heart Association, Inc.

Editorials

Statins for Stroke: The Second Story?

Jorge Plutzky, MD; Paul M. Ridker, MD, MPH

From the Division of Cardiovascular Diseases (J.P., P.M.R.), the Vascular Disease Prevention Program (J.P.), and the Center for Cardiovascular Disease Prevention (P.M.R.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Dr Paul Ridker, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215. E-mail pridker@partners.org

Key Words: Editorials • heart diseases • statins • stroke • cholesterol • lipids

In the 100 years since Ignatovski demonstrated that high-fat diets promote atherosclerosis in rabbits,¹ cardiologists have witnessed an extraordinary evolution in our understanding of atherothrombosis and lipid reduction, culminating in the publication of 5 landmark trials of HMG-CoA reductase inhibition within the past 6 years.^{2 3 4 5 6} In each of these trials, statin therapy was shown to significantly reduce the risks of coronary heart disease in populations with progressively lower degrees of overall risk. These data have had profound effects on preventive medicine and established the first clear success story for this class of therapy.

Despite these triumphs, questions remain in our understanding of statins, how they work, and in what settings. As a result, clinical paradigms regarding cholesterol reduction continue to shift. In this sense, the large meta-analysis from the Prospective Pravastatin Pooling Project, which was published in this issue of Circulation, addresses a question that may represent a second success story for the statins.⁷ Does statin therapy lower the risk of stroke and, if so, why, given the controversy over the role of LDL cholesterol as a risk factor for stroke?

These are some of the issues that Byington and colleagues⁷ address in their analysis of cerebrovascular events in the Prospective Pravastatin Pooling Project, a carefully performed systematic overview including 19 768 patients enrolled in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial, the Cholesterol and Recurrent Events (CARE) study, and West of Scotland Coronary Prevention Study (WOSCOPS), each of which randomly allocated study participants between 40 . . . [Full Text of this Article]

This article has been cited by other articles:

				R. Paumelle, C. Blanquart, O. Briand, O. Barbier, C. Duhem, G. Woerly, F. Percevault, J.-C. Fruchart, D. Dombrowicz, C. Glineur, et al. Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator-Activated Receptor-{alpha} via Inhibition of the Protein Kinase C Signaling Pathway Circ. Res., February 17, 2006; 98(3): 361 - 369. [Abstract] [Full Text] [PDF]

				P. Amarenco and A. M. Tonkin Statins for Stroke Prevention: Disappointment and Hope Circulation, June 15, 2004; 109(23_suppl_1): III-44 - III-49. [Abstract] [Full Text] [PDF]

				T. S. Bowman, H. D. Sesso, J. Ma, T. Kurth, C. S. Kase, M. J. Stampfer, and J. M. Gaziano Cholesterol and the Risk of Ischemic Stroke Stroke, December 1, 2003; 34(12): 2930 - 2934. [Abstract] [Full Text] [PDF]

				S. E. Straus, S. R. Majumdar, and F. A. McAlister New Evidence for Stroke Prevention: Scientific Review JAMA, September 18, 2002; 288(11): 1388 - 1395. [Abstract] [Full Text] [PDF]

				R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]